

Supplementary Table 2. Competing risk analysis for composite kidney outcome

Atherogenic indices	Model 1		Model 2		Model 3	
	SHR (95% CI)	p-value	SHR (95% CI)	p-value	SHR (95% CI)	p-value
AIP per 1.0 increase	1.33 (1.09–1.61)	<0.001	1.62 (1.32–2.00)	<0.001	1.44 (1.15–1.78)	<0.001
Q1	(Reference)		(Reference)		(Reference)	
Q2	1.04 (0.89–1.22)	0.64	1.08 (0.93–1.26)	0.31	1.03 (0.88–1.21)	0.70
Q3	1.02 (0.87–1.20)	0.77	1.05 (0.89–1.22)	0.57	0.97 (0.83–1.15)	0.73
Q4	1.23 (1.06–1.43)	0.007	1.41 (1.21–1.64)	<0.001	1.27 (1.09–1.51)	0.003
TC/HDL-C per 1.0 increase	0.99 (0.95–1.04)	0.71	1.03 (0.98–1.08)	0.23	1.03 (0.98–1.08)	0.24
Q1	(Reference)		(Reference)		(Reference)	
Q2	0.92 (0.79–1.07)	0.3	0.93 (0.80–1.08)	0.36	1.01 (0.86–1.18)	0.88
Q3	0.96 (0.83–1.12)	0.61	1.00 (0.86–1.17)	0.97	1.11 (0.94–1.30)	0.21
Q4	0.87 (0.75–1.02)	0.1	0.98 (0.84–1.15)	0.80	0.99 (0.84–1.17)	0.89
LDL-C/HDL-C per 1.0 increase	0.93 (0.87–0.99)	0.02	0.97 (0.91–1.03)	0.33	0.98 (0.93–1.05)	0.71
Q1	(Reference)		(Reference)		(Reference)	
Q2	0.99 (0.86–1.15)	0.89	0.98 (0.84–1.13)	0.75	1.05 (0.90–1.22)	0.52
Q3	0.95 (0.82–1.10)	0.48	0.94 (0.81–1.09)	0.44	1.02 (0.88–1.20)	0.76
Q4	0.79 (0.67–0.93)	0.004	0.87 (0.74–1.02)	0.08	0.90 (0.76–1.07)	0.25
Non-HDL-C/HDL-C per 1.0 increase	0.99 (0.95–1.04)	0.71	1.03 (0.98–1.08)	0.23	1.03 (0.98–1.08)	0.24
Q1	(Reference)		(Reference)		(Reference)	
Q2	0.92 (0.79–1.07)	0.3	0.93 (0.80–1.08)	0.36	1.01 (0.86–1.18)	0.88
Q3	0.96 (0.83–1.12)	0.61	1.00 (0.86–1.17)	0.97	1.11 (0.94–1.30)	0.21
Q4	0.87 (0.75–1.02)	0.1	0.98 (0.84–1.15)	0.80	0.99 (0.84–1.17)	0.89

Subdistribution hazard model was performed with all-cause death treated as competing risk.

Model 1: unadjusted model; model 2: adjusted for age and sex; model 3: adjusted for age, sex, smoking, and alcohol status, body mass index, systolic blood pressure, hemoglobin, estimated glomerular filtration rate (Chronic Kidney Disease-Epidemiology Collaboration equation), use of lipid-lowering agents, past histories of hypertension, diabetes mellitus, coronary artery disease, cerebral infarction, dyslipidemia, and fatty liver.

AIP, atherogenic index of plasma; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SHR, estimated sub-hazard ratio; TC, total cholesterol.